Research finds experimental eye drops restore light perception in blind mice and zebrafish — Evidence Review

A new animal study shows that photoswitchable small molecule eye drops can restore light perception in blind mice, offering a non-invasive approach to vision restoration. Related research broadly supports the potential for drug-based and optogenetic strategies to reactivate retinal circuits after photoreceptor loss, as demonstrated in studies using gene therapy, growth factors, and other topical treatments (1, 2, 4, 5).

• Several studies confirm that surviving retinal networks can be reactivated to restore vision, either through optogenetic actuators, gene therapy, or pharmacological approaches, lending support to the mechanism targeted in this new study (1, 5).
• Topical therapies, including eye drops with neuroprotective or antioxidant properties, have shown efficacy in animal models for various retinal degenerative conditions, aligning with the non-invasive delivery tested here (2, 4).
• While prior research has demonstrated functional recovery in animal models, translating these findings to lasting, high-quality vision in humans remains a significant challenge, with safety and long-term effects still under investigation (1, 2, 4, 5).

Study Overview and Key Findings

Blinding diseases such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP) affect millions globally, often leaving much of the retinal circuitry intact even after photoreceptor loss. This study addresses the therapeutic gap for patients with advanced degeneration who lack mutation-specific options by developing photoswitchable small molecules that mimic photoreceptor activity. The researchers explored both intravitreal injection and topical eye drop delivery, seeking a patient-friendly and broadly applicable solution for vision restoration.

Property	Value
Organization	Institute for Bioengineering of Catalonia (IBEC), University of Alcalá (UAH), Institut de Química Avançada de Catalunya (IQAC-CSIC), University of Barcelona (UB), Institute Ramón y Cajal of Health Research (IRYCIS), Autonomous University of Barcelona (UAB)
Journal Name	Journal of the American Chemical Society
Authors	Pau Gorostiza, Rosalba Sortino, Pedro de la Villa
Population	Blind mice, zebrafish larvae
Methods	Animal Study
Outcome	Visual responses in animal models of blindness
Results	Prosthe6 restored light perception in blind mice and zebrafish.

Literature Review: Related Studies

We searched the Consensus database, which contains over 200 million research papers, to identify studies relevant to vision restoration, drug delivery, and retinal circuit reactivation. The following queries were used:

1. eye drops vision restoration mice
2. light perception restoration zebrafish
3. experimental treatments blindness outcomes

Topic	Key Findings
How effective are drug- and gene-based interventions for vision restoration after photoreceptor loss?	- Ectopic expression of human rod opsin or multicharacteristics opsin can restore vision in mouse models of retinal degeneration, with visually guided behavior and responses to moderate light levels (1, 5). - BDNF and cerium oxide nanoparticle eye drops protect or restore retinal function in animal models of glaucoma and AMD (2, 4).
What is the potential and mechanism for non-invasive topical treatments (eye drops) in retinal diseases?	- Topical BDNF and cerium oxide nanoparticle eye drops can reach the retina and provide neuroprotection or reduce degeneration in mouse models, supporting the feasibility of non-invasive delivery for retinal therapies (2, 4). - PM2.5 eye drops demonstrate that topical agents can induce or model ocular surface and retinal changes in mice (3).
Can surviving retinal circuits be reactivated to restore functional vision, and how do animal models inform this process?	- Zebrafish and mouse models with photoreceptor loss can regain light responses and visually guided behaviors after experimental treatments, either through pharmacological, genetic, or regenerative interventions (1, 5, 6, 7, 8, 9, 10). - Regenerating or reactivating neural pathways enables partial or full recovery of visual functions in animal models (6, 7, 8, 9, 10).

How effective are drug- and gene-based interventions for vision restoration after photoreceptor loss?

Multiple studies demonstrate that both gene-based and pharmacological interventions can restore visual function in animal models with advanced retinal degeneration. These approaches, including optogenetic actuators like human rod opsin and multicharacteristics opsin, as well as neurotrophic factors and antioxidant nanoparticles, show that even after photoreceptor loss, it is possible to recover light perception and visually guided behavior (1, 2, 4, 5). The new study builds on this by introducing a small molecule alternative that does not require genetic modification or viral delivery.

• Ectopic expression of rod opsin enables mice with retinal degeneration to respond to moderate light under natural conditions, similar to effects observed with photoswitchable molecules (1).
• Intravitreal and topical delivery of BDNF or cerium oxide nanoparticles protects or restores visual function in models of glaucoma and AMD, indicating a range of drug-based strategies are feasible (2, 4).
• The small molecule approach in the new study offers a potentially simpler and more broadly applicable strategy than gene therapy, which is often mutation-specific (1, 5).
• Previous studies show that restored visual behavior can occur at light intensities typical of indoor environments, a criterion met by the new compounds (1, 5).

What is the potential and mechanism for non-invasive topical treatments (eye drops) in retinal diseases?

Research on topical therapies highlights the retina's accessibility to eye drop-delivered molecules, particularly when these are engineered for solubility and stability. Eye drops containing BDNF or cerium oxide nanoparticles reached the retina and achieved therapeutic effects in animal models of glaucoma and AMD (2, 4). The new study's demonstration that photoswitchable drugs delivered as eye drops can reactivate retinal circuits supports the viability of non-invasive approaches for vision restoration, while also showing behavioral improvement in animal models.

• Topical BDNF improved retinal ganglion cell survival and visual function, independent of intraocular pressure changes, in glaucoma models (2).
• Cerium oxide nanoparticle eye drops reduced oxidative stress and neovascularization in AMD models, supporting neuroprotection and disease modification (4).
• The delivery of PM2.5 via eye drops produced ocular changes in mice, demonstrating that the route is effective for reaching deeper ocular tissues (3).
• The new study confirms that photoswitchable compounds administered as eye drops can restore light-avoidance behavior in blind mice, with no need for invasive procedures (2, 4).

Can surviving retinal circuits be reactivated to restore functional vision, and how do animal models inform this process?

A consistent theme in animal research is the preservation of inner retinal neurons and circuits even after the loss of photoreceptors. Various studies show that these surviving networks can be reactivated by introducing new light-sensitive proteins, drugs, or by promoting endogenous regeneration, leading to partial or robust recovery of visual behaviors (1, 5, 6, 7, 8, 9, 10). The new photoswitchable small molecules act at the level of ON bipolar cells, a strategy similarly targeted by some optogenetic therapies, and animal models confirm that such interventions can restore functional light responses.

• Zebrafish and mouse models demonstrate that visual function can recover following photoreceptor ablation, either through regeneration or circuit reactivation (6, 7, 8, 9, 10).
• Regenerated photoreceptors in zebrafish can reintegrate into the retinal circuitry and restore color and contrast vision, albeit over a period of days to months (8, 9).
• Behavioral recovery, such as light avoidance or optokinetic responses, is commonly used to assess the return of functional vision in animal studies and was used in the new study (1, 5, 7, 8, 10).
• The new study's use of both mice and zebrafish aligns with established models in the field and supports the translational relevance of its findings (1, 5, 6, 7, 8, 9, 10).

Future Research Questions

Further research is needed to determine the clinical potential, safety, and mechanisms of photoswitchable small molecule therapy for vision restoration. Unanswered questions include the duration of effect, translation to human patients, and the long-term impact on retinal health.

Research Question	Relevance
What are the long-term effects and safety of photoswitchable small molecules for vision restoration in mammals?	Long-term safety and efficacy data are essential before the approach can be considered for human trials. Previous studies of topical and gene therapies highlight the need for chronic safety assessments (1, 2, 4).
Can photoswitchable small molecule therapies restore high-quality vision in humans with advanced retinal degeneration?	Translational research is needed to assess whether the effects observed in animal models will apply to human patients, as human retinal structure and disease progression may differ (1, 5, 8).
How do photoswitchable drugs compare with gene therapy and optogenetics in effectiveness and accessibility?	Comparative studies are necessary to determine whether non-genetic, drug-based approaches offer advantages in terms of vision quality, patient accessibility, and cost-effectiveness (1, 5).
What are the mechanisms of retinal circuit reactivation with photoswitchable compounds?	Understanding the precise cellular and molecular mechanisms will inform optimization of drug design and delivery, as well as identify potential off-target effects (1, 5, 8, 9).
Can combining photoswitchable molecules with other neuroprotective or regenerative therapies enhance vision restoration?	Combining strategies, such as neuroprotection with BDNF or promoting regeneration, may result in greater and more durable improvements in visual function (2, 4, 6, 8, 9).